BioNTech CEO sold shares under plan

What happened

BioNTech SE (NASDAQ: BNTX) filed a Form 4 showing Ugur Sahin sold 66,000 ordinary shares on 2026-09-29 and 2026-09-30. He is listed as Chief Executive Officer and a 10% owner, and the sales were made under a Rule 10b5-1 trading plan.

He sold 34,000 shares on 2026-09-29 at $98.2591, leaving 246,209, and 32,000 shares on 2026-09-30 at $98.1203, leaving 214,209. The sales totaled about $6.48 million.

The form says the ordinary shares are held by Medine GmbH, which Sahin solely owns, and 106,721 of those are held in trust.

Key numbers

Metric	Latest	Change	Source
Shares sold	66,000 shares		SEC Form 4
Sale price	$98.12 to $98.26 per share		SEC Form 4
Sale value	about $6.48 million		SEC Form 4
Shares held afterward	214,209 shares		SEC Form 4
Indirect shares held through Medine GmbH	39,218,111 ordinary shares		SEC Form 4

Read more: BioNTech (BNTX) stock analysis and investment case

Why it matters

OptimistFi's case is that BioNTech needs its mRNA and immunotherapy platform to become a durable non-COVID oncology business before vaccine cash flows and R&D losses erode option value. This filing shows Sahin trimmed direct ownership in two sales, on 2026-09-29 and 2026-09-30, under a plan established on June 3, 2026. OptimistFi calculates the 66,000 shares were about 23.6% of the holding before the trade.

The caveat is that the filing itself says the trades were made under a Rule 10b5-1 plan, which can reflect a preset schedule rather than a fresh view. Sahin still held 214,209 shares afterward, so the sale does not stand alone as a clear signal about the business. The form also lists 39,218,111 ordinary shares held indirectly through Medine GmbH. One footnote says Sahin may be deemed to beneficially own those shares.

The filing also says 106,721 of the ordinary shares noted there are held for the benefit of an individual under a trust arrangement. That detail shows the reported ownership picture includes both direct and indirect holdings.

Related: BioNTech Ends Cancer-Vaccine Trial, Raising Stakes for Oncology

What's next

BioNTech's next quarterly report is the next scheduled test. Investors will look for whether it adds oncology evidence or shows continued losses and cash use. A report with more oncology output would strengthen OptimistFi's case, while a weaker report would keep attention on the gap between the platform story and the cash burn.

More from OptimistFi